Efficacy and safety of Wuling San for treatment of breast-cancer-related upper extremity lymphoedema: study protocol for a pilot trial

Huiru Zhu, Zheng Peng, Meiyu Dai, Yan Zou, Fengxian Qin, Jifei Chen, Liuying Song, Baoyu He, Xiaolan Lv, Shengming Dai, Huiru Zhu, Zheng Peng, Meiyu Dai, Yan Zou, Fengxian Qin, Jifei Chen, Liuying Song, Baoyu He, Xiaolan Lv, Shengming Dai

Abstract

Introduction: Breast-cancer-related upper extremity lymphoedema (BCUL), a common complication of mastectomy, can cause physical discomfort, psychological distress, cosmetic defects, functional disability and chronic recurrent erysipelas in the affected arm(s). It is a challenge to physicians involved in the management of these patients. Wuling San, a classic prescription in Traditional Chinese Medicine used in treating oedema for thousands of years, is reported by many Chinese journals to perform well in BCUL. Therefore, the aim of this study is to verify its efficacy and evaluate its safety using rigorous methodological designs in patients with BCUL.

Methods and analysis: To verify the efficacy and assess the safety of Wuling San over a placebo, this double-blind, randomised, placebo-controlled, multicentre trial will be carried out in three hospitals. A total of 200 eligible patients with BCUL will be randomly allocated, in a ratio of 1:1, to either the experimental medicine group or the placebo group. The primary outcome measure will be the proportion of absolute reduced limb volume, as measured by perometry. The second outcome measure will be the number of participants with adverse events. The assessment will be carried out at the following time points: before enrolment (baseline) and 2, 4, 6 and 8 weeks after treatment.

Ethics and dissemination: This trial will be conducted in accordance with the Declaration of Helsinki and supervised by the institutional review board of the Fourth Affiliated Hospital of Guangxi Medical University (approval number PJK2016088). All patients will receive information about the trial in verbal and written forms and will give informed consent before enrolment. This trial will help to demonstrate whether Wuling San is effective in the treatment of patients with BCUL. The results will be published in peer-reviewed journals or disseminated through conference presentations.

Trial registration number: NCT02726477; Pre-results.

Keywords: Wuling San; lymphedema; protocol.

Conflict of interest statement

Conflicts of Interest: None declared.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Flow chart.

References

    1. Maclellan RA, Greene AK. Lymphedema. Semin Pediatr Surg 2014;23:191–7. 10.1053/j.sempedsurg.2014.07.004
    1. Coriddi M, Khansa I, Stephens J et al. . Analysis of factors contributing to severity of breast cancer-related lymphedema. Ann Plast Surg 2015;74:22–5. 10.1097/SAP.0b013e31828d7285
    1. Paskett ED, Dean JA, Oliveri JM et al. . Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol 2012;30:3726–33. 10.1200/JCO.2012.41.8574
    1. Ridner SH. Pathophysiology of lymphedema. Semin Oncol Nurs 2013;29:4–11. 10.1016/j.soncn.2012.11.002
    1. Chachaj A, Malyszczak K, Pyszel K et al. . Physical and psychological impairments of women with upper limb lymphedema following breast cancer treatment. Psychooncology 2010;19:299–305. 10.1002/pon.1573
    1. Deng J, Fu MR, Armer JM et al. . Factors associated with reported infection and lymphedema symptoms among individuals with extremity lymphedema. Rehabil Nurs 2015;40:310–19. 10.1002/rnj.171
    1. Granzow JW, Soderberg JM, Dauphine C. A novel two-stage surgical approach to treat chronic lymphedema. Breast J 2014;20:420–2. 10.1111/tbj.12282
    1. Taghian NR, Miller CL, Jammallo LS et al. . Lymphedema following breast cancer treatment and impact on quality of life: a review. Crit Rev Oncol Hematol 2014;92:227–34. 10.1016/j.critrevonc.2014.06.004
    1. Maclellan RA, Couto RA, Sullivan JE et al. . Management of primary and secondary lymphedema: analysis of 225 referrals to a center. Ann Plast Surg 2015;75:197–200. 10.1097/SAP.0000000000000022
    1. Jiang M, Lu C, Zhang C et al. . Syndrome differentiation in modern research of traditional Chinese medicine. J Ethnopharmacol 2012;140:634–42. 10.1016/j.jep.2012.01.033
    1. Yu F, Takahashi T, Moriya J et al. . Traditional Chinese medicine and Kampo: a review from the distant past for the future. J Int Med Res 2006;34:231–9.
    1. Ehling D. Oriental medicine: an introduction. Altern Ther Health Med 2001;7:71.
    1. Chen FP, Chen FJ, Jong MS et al. . Modern use of Chinese herbal formulae from Shang-Han Lun. Chin Med J 2009;122:1889.
    1. Luo C, Huang L. Clinical observation on treatment of upper limb lymphedema after breast cancer operation using modified Wulingsan formula. Liaoning J Tradit Chin Med 2006;33:1132–2.
    1. Dong J, Yi J. Recent developement of breast cancer treatment by traditional Chinese medicine and neoadjuvant chemotherapy. Guangming J Chin Med 2008;23:689–91.
    1. Li X. Treatment of 100 cases special edema using adjusted Wuling powder. Hebei J Tradit Chin Med 1999;21:24–24.
    1. Liu S, Yin D. Clinical observation on 92 cases of breast cancer treated by traditional Chinese medicine. Jilin J Tradit Chin Med 2008;28:333–4.
    1. Andersen L, Hojris I, Erlandsen M et al. . Treatment of breast-cancer-related lymphedema with or without manual lymphatic drainage-a randomized study. Acta Oncol 2000;39:399–405.
    1. Lyman GH, Temin S, Edge SB et al. . Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2014;32:1365–83. 10.1200/JCO.2013.54.1177
    1. Penha TR, van Roozendaal LM, Smidt ML et al. . The changing role of axillary treatment in breast cancer: who will remain at risk for developing arm morbidity in the future? Breast 2015;24:543–7. 10.1016/j.breast.2015.04.008
    1. Badger C, Preston N, Seers K et al. . Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev 2004;(4):Cd003141 10.1002/14651858.CD003141.pub2
    1. Stuiver MM, ten Tusscher MR, Agasi-Idenburg CS et al. . Conservative interventions for preventing clinically detectable upper-limb lymphoedema in patients who are at risk of developing lymphoedema after breast cancer therapy. Cochrane Database Syst Rev 2015;(2):Cd009765 10.1002/14651858.CD009765.pub2
    1. Moseley AL, Carati CJ, Piller NB. A systematic review of common conservative therapies for arm lymphoedema secondary to breast cancer treatment. Ann Oncol 2007;18:639–46. 10.1093/annonc/mdl182
    1. Yang Y, Zhang DM, Liu JH et al. . Wuling San protects kidney dysfunction by inhibiting renal TLR4/MyD88 signaling and NLRP3 inflammasome activation in high fructose-induced hyperuricemic mice. J Ethnopharmacol 2015;169:49–59. 10.1016/j.jep.2015.04.011
    1. Ding XQ, Pan Y, Wang X et al. . Wuling san ameliorates urate under-excretion and renal dysfunction in hyperuricemic mice. Chin J Nat Med 2013;11:214–21. 10.1016/S1875-5364(13)60019-9
    1. Jin R, Yu R, Gao H et al. . Comparative study of Wuling powder and Wuling decoction for nephrotic syndrome patients of water-damp collecting internally syndrome. J Tradit Chin Med 2012;53:572–577.
    1. Ahn YM, Cho KW, Kang DG et al. . Oryeongsan (Wulingsan), a traditional Chinese herbal medicine, induces natriuresis and diuresis along with an inhibition of the renin–angiotensin–aldosterone system in rats. J Ethnopharmacol 2012;141:780–5. 10.1016/j.jep.2012.02.021
    1. He L, Rong X, Jiang JM et al. . Amelioration of anti-cancer agent adriamycin-induced nephrotic syndrome in rats by Wulingsan (Gorei-San), a blended traditional Chinese herbal medicine. Food Chem Toxicol 2008;46:1452–60. 10.1016/j.fct.2007.12.005
    1. Xiong KW, Lin SG, Zhong L et al. . Clinical observation of Wuling San in the treatment of early diabetic nephropathy edema. J. Clin. Exp.Med 2011;10:1023–4.
    1. Lee SM, Lee YJ, Yoon JJ et al. . Effect of Poria cocos on hypertonic stress-induced water channel expression and apoptosis in renal collecting duct cells. J Ethnopharmacol 2012;141:368–76. 10.1016/j.jep.2012.02.048
    1. Zhao YY, Lei P, Chen DQ et al. . Renal metabolic profiling of early renal injury and renoprotective effects of Poria cocos epidermis using UPLC Q-TOF/HSMS/MS E. J Pharm Biomed Anal 2013;81-82:202–9. 10.1016/j.jpba.2013.03.028
    1. Hsu PC, Tsai YT, Lai JN et al. . Integrating traditional Chinese medicine healthcare into diabetes care by reducing the risk of developing kidney failure among type 2 diabetic patients: a population-based case control study. J Ethnopharmacol 2014;156:358–64. 10.1016/j.jep.2014.08.029
    1. Zhang G, Zeng X, Han L et al. . Diuretic activity and kidney medulla AQP1, AQP2, AQP3, V 2 R expression of the aqueous extract of sclerotia of Polyporus umbellatus fries in normal rats. J Ethnopharmacol 2010;128:433–7. 10.1016/j.jep.2010.01.032
    1. Feng YL, Chen H, Tian T et al. . Diuretic and anti-diuretic activities of the ethanol and aqueous extracts of Alismatis Rhizoma. J Ethnopharmacol 2014;154: 386–90. 10.1016/j.jep.2014.04.017
    1. Fan LC, Yin CP, Liu JH et al. . Study on effect of aqueous extract from Alisma Orientatis on urinary oxalate calcium stone formation. China Pharm 2010;13:1701–4.
    1. Ozbayer C, Kurt H, Ozdemir Z et al. . Gastroprotective, cytoprotective and antioxidant effects of Oleum cinnamomi on ethanol induced damage. Cytotechnology 2014;66:431–41. 10.1007/s10616-013-9594-y
    1. Guo L, Sun YL, Wang AH et al. . Effect of polysaccharides extract of rhizoma atractylodis macrocephalae on thymus, spleen and cardiac indexes, caspase-3 activity ratio, Smac/DIABLO and HtrA2/Omi protein and mRNA expression levels in aged rats. Mol Biol Rep 2012;39:9285–90. 10.1007/s11033-012-1677-x

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner